The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.
September 7th 2021
The combination of pembrolizumab and lenvatinib led to a statistically significant improvement in progression-free survival and overall survival in patients with mismatch repair deficient advanced endometrial cancer following platinum-based chemotherapy.
August 25th 2021
Ramez N. Eskander, MD, discusses the utility of lymphadenectomy in patients with endometrial cancer.
August 20th 2021
The use of transvaginal ultrasonography to measure the need for diagnostic testing of endometrial cancer missed almost 5 times more endometrial cancer cases in Black women compared with those in White women.
August 18th 2021
The FDA has approved the VENTANA MMR RxDx panel as the first companion diagnostic test to assist in identifying patients with solid tumors that are DNA mismatch repair deficient who may be eligible to receive the anti–PD-1 therapy dostarlimab-gxly, which was recently granted an accelerated approval by the agency.
August 18th 2021
The FDA has granted a fast track designation to STRO-002 as a potential therapeutic option for patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have previously received 1 to 3 lines of systemic therapy.
August 17th 2021
The FDA has granted an accelerated approval to dostarlimab-gxly for the treatment of adult patients with mismatch repair-deficient recurrent or advanced solid tumors, as determined by an FDA-approved test, who have progressed on or following previous treatment and who have no satisfactory alternative options.
August 16th 2021
The FDA has granted a fast track designation to IN10018 as a potential therapeutic option for use in patients with platinum-resistant ovarian cancer.
August 10th 2021
The FDA has accepted a new supplemental biologics license application that is seeking the approval of pembrolizumab for use as a monotherapy in patients with advanced endometrial carcinoma that is microsatellite instability–high or mismatch repair deficient, who have progressed after systemic therapy in any setting and are not eligible for curative surgery or radiation.
July 22nd 2021
The FDA has granted a regular approval to pembrolizumab plus lenvatinib for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability high or mismatch repair deficient, who have disease progression after previous systemic therapy in any setting, and who are not candidates for curative surgery or radiation.
July 14th 2021
Patients with mismatch repair–deficient recurrent or advanced endometrial cancer gained an efficacious and safe treatment option with the addition of dostarlimab-gxly.
July 9th 2021
Molecular characterization of endometrial tumors has resulted in a boom of investigative efforts aimed at ushering in a new era of tailored therapeutic regimens for patients with these malignancies.
July 5th 2021
Dr. O’Malley discusses key findings from 6 trials that were presented at the virtual 2021 SGO Annual Meeting on Women’s Cancer.
July 1st 2021
Novel therapeutic strategies are poised to expand in adjuvant settings for patients with early-stage disease facing recurrence risks in the treatment paradigms for a range of tumor types after positive data from large phase 3 clinical trials were highlighted at the 2021 American Society of Clinical Oncology Annual Meeting
June 29th 2021
Practice-validating trials in cervical cancer, endometrial cancer, and ovarian cancer were the focus of the 2021 ASCO Annual Meeting in gynecologic oncology, each carrying relevant implications on extended therapy, surveillance, and biomarker testing.
June 22nd 2021
Pembrolizumab plus platinum-based chemotherapy with or without bevacizumab significantly improved overall survival and progression-free survival over the same platinum-based chemotherapy regimen with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer—irrespective of PD-L1 status.
June 17th 2021
The FDA has granted priority review to the biologics license application for balstilimab for use in the treatment of patients with recurrent or metastatic cervical cancer who experienced disease progression on, or after, chemotherapy.
June 8th 2021
The antibody-drug conjugate vic-trastuzumab duocarmazine was found to significantly improve progression-free survival over physician’s choice of treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer, meeting the primary end point of the phase 3 TULIP trial.
June 7th 2021
The combination of pertuzumab and trastuzumab elicited a 37% disease control in patients with ERBB2/ERBB3-expressed, mutated, or -amplified uterine cancer.
June 7th 2021
OncLive sits down with Nicholas J. Vogelzang, MD, and Erin K. Crane, MD, MPH to discuss the biggest abstracts in genitourinary cancers and gynecologic cancers, respectively, at the 2021 ASCO Annual Meeting.